Enveric Biosciences, Inc. ENVB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-75.09
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$8.8M | — | — | $4.2M |
| 2024 | — | -$9.6M | — | — | $1.6M |
| 2023 | — | -$17.3M | — | -$14.1M | $2.0M |
| 2022 | — | -$18.5M | — | -$17.7M | $14.7M |
| 2021 | — | -$49.0M | — | -$11.6M | $22.3M |
| 2020 | — | -$6.9M | — | — | $3.4M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -75.09 (distress)
- Working capital / assets 0.789
- Retained earnings / assets -22.537
- EBIT / assets -1.722
- Equity / liabilities 4.549
Source: SEC EDGAR filings · CIK 0000890821 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.